What 46 Drugs Approved in 2025 Reveal About Payer Evidence Expectations FDA approval is often treated as the defining milestone for a new medicine. But approval alone does not guarantee
Gilead to Acquire Arcellx in $7.8B Deal for Multiple Myeloma Cell Therapy Summary Gilead Sciences has announced its acquisition of Arcellx, its longtime development partner, for $7.8 billion. This deal
Lilly Acquires Orna Therapeutics to Advance Cell Therapy for Autoimmune Diseases Summary Lilly has announced its acquisition of Orna Therapeutics, a biotechnology startup specializing in circular RNA medicines. The deal,
Summary The Trump administration has launched an online portal called TrumpRx that offers around 40 drugs from select manufacturers at discounted prices. However, the impact of this service may be
Novo Combination Obesity Shot Meets Goal in Diabetes Trial Summary Novo Nordisk announced positive results from a Phase 3 trial for their experimental combination shot, CagriSema, in people with diabetes
Drugs for Cancer, Arthritis, and HIV on Medicare’s List for 2028 Price Cuts Summary The federal government has announced the next 15 medicines for which it will seek price reductions
Summary The Trump administration has announced two new Medicare pilot programs, “Globe” and “Guard”, that aim to lower drug prices by tying rebates to prices paid in comparable countries. Tanabe
Biopharma Climbs Higher as 9 Drugmakers Ink ‘Pandering’ Drug Price Deals with Trump Summary Nine drugmakers have recently inked deals with President Trump to offer discounts on specific drugs in
Summary BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics in an all-cash deal worth $4.8 billion. This deal is expected to close between April and June of next year
Summary: Insmed, a biotechnology company, experienced a significant drop in their stock price after announcing that their drug brensocatib failed a Phase 2b study for a chronic nasal condition. This